ZMS-2195

ZMS-2195 is a novel, orally bioavailable, and highly potent multi-RAS inhibitor designed to target a broad spectrum of RAS mutations, including KRAS, NRAS, and HRAS variants, as well as wild-type RAS. Developed by Zemisen, the compound functions by disrupting the interaction between the RAS-RAF complex, specifically targeting the RAF-RBD domain. In preclinical studies, ZMS-2195 demonstrated robust inhibition of the MAPK pathway, as evidenced by significant suppression of phosphorylated ERK (pERK) and reduced human DUSP6 mRNA expression levels in tumor lysates. It has shown potent anti-tumor activity in xenograft models of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). By hitting a wider range of RAS targets than single-mutant inhibitors, ZMS-2195 is intended to overcome resistance and provide therapeutic benefit across diverse RAS-driven malignancies, including those activated by upstream mutations.

Other names

ZMS-2159ZMS2159ZMS 2159